SYNEXA
Delivering Quality, Clinically-Relevant Science on Time and within Budget

Synexa provides clients with a broad spectrum of analytical and advising services, including biomarker and bioanalytical readout identification, development, validation, analysis, and interpretation in translational and clinical research. Synexa was established in 2003 as a forerunner in the field of biomarker science. Since then, the company has steadily grown to become a recognized leader in the field of biomarker and bioanalytical science.

Gilde Healthcare, a specialized European healthcare investor, has supported Synexa, a privately held company. Synexa is led by a growing team of experienced scientists and business leaders, with over 70 scientists working across three labs. For over 20 years, synexa life sciences have been providing expert insights into the clinical development of therapeutics.

The company’s collaborative approach to providing tailored, multi-faceted, and flexible solutions to a client’s individual demands reflects Synexa Life Sciences’ guiding values. The company takes pride in developing, executing, and integrating the most effective analytical and data insight approaches to help advance scientific understanding. This translates to better healthcare administration and treatment, resulting in a better world.

Synexa is a world leader in biomarker and bioanalytical science, with extensive knowledge of the immunological basis of health and disease. The company provides clients with a broad spectrum of analytical and advising services, including biomarker and bioanalytical readout identification, development, validation, analysis, and interpretation in translational and clinical research. Synexa’s growing global network of labs serves a largely Biotech and Pharma client base, either directly or through a CRO.

Synexa is committed to offering high-quality, clinically relevant solutions, and all activities are carried out in accordance with GCLP, which includes the appropriate GCP/GLP criteria, and under the guidance and supervision of their Quality Assurance team. Synexa answers client-specific concerns about biomarkers at every level of the biological continuum, including questions about biomarker development, validation, and data interpretation, using new methodologies and validated platforms. They collaborate with their clients to develop personalized, flexible, and multi-faceted biomarker solutions.
The company uses an integrated strategy across the biological continuum to gain a better understanding of drug/target interactions at a molecular level, as well as gather reliable data and biological responses across a variety of biological specimens ranging from nucleic acids to tissue. Synexa combines a world-class scientific basis with professional service delivery across a wide range of therapeutic areas, integrating solid scientific and regulatory knowledge with the newest technological platforms and experience. Synexa also excels in developing and validating bespoke end-to-end solutions to match your specific needs. Custom bioassay solutions are combined with tried-and true sophisticated technology platforms that can assess biomarkers across the biological spectrum and deliver reliable results.

Moreover, Synexa’s worldwide infrastructure is designed to help partners with everything from preclinical translational research and biomarker development through clinical bioanalysis of both established and innovative medication modalities. Synexa’s ProtoTrials® human in vitro translational platform bridges the gap between animal models and humans, making it perfect for PD, Safety, Drug Benchmarking, and Biomarker Discovery applications. Synexa has a wealth of experience in large molecule bioanalysis, having worked with biopharma partners through all stages of technique development, validation, and clinical application. Synexa has decades of experience creating and implementing effective biomarker methodologies, offering Insights that will improve the quality of decision-making throughout the development of a treatment.